OBJECTIVE: To conduct an economic evaluation of switching from the current regime using combination of DTwcPHib + OPV to new combined vaccine DTwcPHib + IPV(monovalent) and DTacPHibIPV(combination). METHODS: Incremental cost-effectiveness approach was used in the methodology. Cost of the vaccination programmes includes price of vaccines, cost of vaccine wastage, cost of transportation and maintenance of cold chain, cost of vaccines administration and cost of managing adverse events. The outcomes measured in this study are the number of cases of Vaccine Associated Paralytic Polio (VAPP) and other adverse events avoided such as mild fever, high fever and convulsions. A time-motion survey was conducted in one government health centre to obtain the human resource cost of vaccine administration. Cost of VAPP was estimated from an expert group discussion while the cost of other adverse events (high fever and mild fever) was obtained from interviews with 400 mothers and children attending three government clinics. The cost of managing convulsions was obtained from a survey of 46 patients admitted to HUKM and Hospital Kuala Lumpur. RESULTS: The current program at the cost of RM 77.14 per dose of DTwcPHib +OPV vaccine would cost the country of RM115 million annually. At RM 91.98 per dose of DTwcPHib +IPV (monovalent), the total cost of program would incur RM137 million and at RM 85.94 per dose of the DTacPHib IPV, the total cost of program was RM128 million. Incremental cost effectives ratio when switching from current programme to DTwcPHib +IPV cost RM 11 million per case of VAPP avoided. However, the incremental cost effectiveness ratio when switching form current programme to DTacPHibIPV cost only RM three million per case of VAPP avoided. CONCLUSIONS: Switching from the current programme to DTacPHib IPV (combination) is more cost-effective as compared to DTwcPHib +IPV (monovalent).